PDS Biotechnology Corporation · NASDAQ:PDSB
PDS Biotechnology — Investor Presentation (March 2022)
25 slides from PDS Biotechnology's investor presentation, Mar 15, 2022

Slide 1: Investor Presentation
INVESTOR PRESENTATION Precision Designed Science For Immunotherapy NASDAQ: PDSB | March 2022

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activi

Slide 3: Company Overview
Clinical-stage Company developing molecularly targeted 1 immunotherapies to treat cancer and infectious disease Versamune® and Infectimune™ platforms leverage the body’s own 2 defense systems to induce disease-specific killer T-cells and antibodies to combat cancer and infectious disease The initial

Slide 4: Versamune Oncology Platform
Versamune ® Oncology Platform

Slide 5: The PDS Biotech Differentiation
The PDS Biotech Differentiation Versamune® is designed to promote powerful, CD8+ killer T-cell responses in vivo Versamune®-based therapies also show promising potential to: Generate the right type and quantity of effective CD8+ killer T-cells 15-30% Success in checkpoint inhibitor treatments due to

Slide 6: Versamune Platform
Versamune® Platform Designed to Recruit, Train and Arm T-cells in the Body References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536

Slide 7: Versamune Platform Oncology Pipeline
Versamune® Platform Versamune®-based oncology pipeline is being developed in partnership with the leaders in immuno oncology Candidate Indication Combination PC P1 P2 P3 R Partner(s) PDS0101 (HPV16) Recurrent/metastatic HPV16-positive head KEYTRUDA VERSATILE-002 and neck cancer (standard of care) Ar

Slide 8: PDS0101: Lead Asset
PDS0101: Lead Asset US HPV-associated cancer Designed to treat human papillomavirus incidence2 (HPV16)-associated cancers Penile Vaginal 3% 2% $6B Market Opportunity1 Vulvar 9% More than 46,0002 patients were estimated to have been diagnosed last year with HPV-associated cancers in the US1,2 Anal He

Slide 9: Phase 2: PDS0101 + M9241 + Bintrafusp alfa
Phase 2: PDS0101 + M9241 + Bintrafusp alfa Investigator-led trial evaluating the combination in patients with advanced refractory HPV-associated cancers Indication Treatment of patients with HPV16-associated cancer who have failed prior treatment Bintrafusp alfa: Bifunctional fusion protein targetin

Slide 10: PDS0101: Triple Combination
PDS0101: Triple Combination Promising survival of patients with advanced refractory HPV16-associated cancers PDS0101 + Bintrafusp alfa + M9241 Indications targeted in study–cervical, anal, head and neck, vaginal, penile Median Survival In Survival: 12+ mo. As of 12/31/21: Patients 3:1 ratio refracto

Slide 11: Triple Combo: PDS0101 + bintrafusp alfa + M9241
Triple Combo: PDS0101 + bintrafusp alfa + M9241 Advanced cancer patients with tumor shrinkage who had failed prior therapy HPV-16 67% (12/18)* PDS0101: Positive Triple Combo Versamune® induced HPV-16 CD8+ killer T-cells HPV-16 0% (0/7) Negative Historical Check Point Inhibitor 12% -24% Efficacy 0% 2

Slide 12: Phase 2: PDS0101 + KEYTRUDA
Phase 2: PDS0101 + KEYTRUDA® Company-sponsored trial for the treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) Indication Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread or returned KEYTRUDA®(Standard of Care): Anti-PD1 check

Slide 13: Phase 2: PDS0101 + Chemoradiotherapy
Phase 2: PDS0101 + Chemoradiotherapy Investigator-led trial evaluating the combination in patients with locally advanced cervical cancer (IMMUNOCERV) Indication Treatment of patients with locally advanced cervical cancer–Stages IB3-IVA Chemoradiotherapy (CRT –Standard of Care): Cisplatin and radiati

Slide 14: Phase 2: PDS0101 Monotherapy and in Combination with KEYTRUDA
Phase 2: PDS0101 Monotherapy and in Comb. with KEYTRUDA® Investigator-led trial evaluating treatments in patients with HPV-associated oropharyngeal cancer with high risk of recurrence Indication Treatment of patients with oropharyngeal cancer prior to transoral robotic surgery KEYTRUDA®: Cisplatin a

Slide 15: PDS0102: TARP Antigen
Pre-Clinical Optimization Studies1: PDS0102: TARP TARP-Specific T-cell Induction after 2 injections of PDS0102 Antigen 1000 Versamune®-induced CD8+ IFN-y ELISPOT Study killer T-cells may result in the 900 Range of observed ability to treat TARP positive 800 T-cell responses Number of TARP-Specific T

Slide 16: PDS0103: MUC1 Antigen
PDS0103: MUC1 Antigen # of Antigen-Recognizing CD8+ T- Cells IFN-γSpot Forming Cells/1X106Spleen Cells Greater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in the ability to treat breast, ovarian, lung, and colon cancers $100B MUC1 Total Market Opportunity* Induced a >10

Slide 17: Projected Milestones Through 1Q 2023
Projected Milestones Through 1Q 2023* 1H21 2H21 1Q22 2Q22 3Q22 4Q22 1Q23 Interim data from HPV-associated cancer trial ASCO - (NCI) Preliminary data from VERSATILE- 002 (KEYTRUDA® combo) (go, no go) Achieved enrollment objective of HPV- associated cancer trial CPI refractory arm (NCI) PDS0101 Antici

Slide 18: Infectimune Infectious Disease Platform
Infectimune™ Infectious Disease Platform

Slide 19: PDS Biotech's Infectimune Pipeline
PDS Biotech’s Infectimune™ Pipeline Developed in partnership with leaders in infectious disease Candidate Indication PC P1 P2 P3 R Partner(s) PDS0202 Universal prevention (influenza) of influenza PDS0203 Prevention of (SARS-CoV-2) COVID-19 PDS0201 Prevention of (M-tuberculosis) tuberculosis PDS Biot

Slide 20: PDS0202: Universal Prevention of Influenza
PDS0202: Universal Prevention of Influenza Provided Effective Neutralization Against Multiple Strains of Flu Viruses in Preclinical Study Average HAI Neutralization Titer Levels Induced by PDS0202 for Various Flu Strains vs Required Levels H1 flu protein + Infectimune 800 H1 flu protein 760 Average

Slide 21: PDS0202: Universal Prevention of Influenza
PDS0202: Universal Prevention of Influenza Provided Protection in Preclinical Study in Keeping Subjects Alive and Healthy Against Challenge with Flu Virus % of Protection of Subjects Challenged with the Flu Virus 100% 100% 100% 100% % of Protection 30% 0% 0% 0% Alive Healthy Alive Healthy Alive Heal

Slide 22: Infectimune Pipeline Highlights
Universal Flu • Announced agreement for license with University of Georgia for universal flu antigens • Top-line preclinical data released Infectimune™ • Preclinical data to be submitted to peer reviewed Pipeline Highlights journal for publication and future conferences COVID • Agreement with Farmac

Slide 23: PDS Biotech Management
PDS Biotech Management Historical success in the development and commercialization of leading pharmaceutical products • Senior executive experience with management of strategy and execution at both large pharma and biotechs Frank Bedu-Addo, PHD • Notable drug development: Chief Executive Officer Abe

Slide 24: Company Overview
Clinical-stage Company developing molecularly targeted 1 immunotherapies to treat cancer and infectious disease Versamune® and Infectimune™ platforms leverage the body’s own 2 defense systems to induce disease-specific killer T-cells and antibodies to combat cancer and infectious disease The initial

Slide 25: Investor Presentation
INVESTOR PRESENTATION Precision Designed Science For Immunotherapy NASDAQ: PDSB | March 2022
Source: Internet Archive copy of pdsbiotech.com
More decks from PDS Biotechnology Corporation
Investor Presentation (October 2026)28 slides · Oct 21, 2026
Investor Presentation (September 2026)28 slides · September 2026
Q1 2026 Earnings Presentation21 slides · May 13, 2026
Investor Presentation (April 2026)21 slides · Apr 24, 2026
Investor Presentation (February 2026)22 slides · Feb 23, 2026
Investor Presentation (February 2026)22 slides · February 2026